# Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis

> **NCT00004482** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 40 (—)

## Conditions studied

- Myocarditis
- Giant Cell Myocarditis

## Interventions

- **DRUG:** Cyclosporine
- **DRUG:** methylprednisolone
- **DRUG:** Muromonab-CD3
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT00004482
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-12
- **Primary completion:** 2005-07
- **Final completion:** 2006-07
- **Target enrollment:** 40 (—)
- **Last updated:** 2010-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004482, "Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00004482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*